Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Comparison of changes in levels of soluble protein biomarkers (VEGF, sVEGFR-2, and sVEGFR-3) in patients with partial response (PR) vs. patients that did not achieve partial response (Non-PR). The sample size listed for each group in each case refers to the number of ratios to baseline represented within the different intervals.

From: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

  Mean Fold Change P value
PR (n) Non-PR (n) (t-test; rank sum)
VEGF    
   All timepoints (cycles 1–3) 5.22 (123) 2.87 (122) 0.0022; 0.035
   All day 28 timepoints (cycles 1–3) 7.91 (74) 3.94 (75) 0.0005; 0.0001
sVEGFR-2    
   All timepoints (cycles 1–3) -1.73 (123) -1.57 (121) 0.0082; 0.001
   All day 28 timepoints (cycles 1–3) -2.12 (74) -1.79 (75) 0.0003; 0.0003
sVEGFR-3    
   All timepoints (cycles 1–3) -1.63 (123) -1.51 (123) 0.108; 0.104
   All day 28 timepoints (cycles 1–3) -2.17 (74) -1.89 (76) 0.010; 0.042
  1. n = number of post-treatment:baseline ratios in each group.